1. Introduction {#sec1}
===============

Few studies have been performed in Egypt concerning the coexistence of genes encoding aminoglycoside-modifying enzymes (AMEs) and plasmid-mediated quinolone resistance (PMQR) among isolates of*Klebsiella pneumoniae*. The present study investigated the prevalence and coexistence of seven genes encoding AMEs and nine genes encoding PMQR. Also, clonal relatedness between*K. pneumoniae* isolates was determined by the enterobacterial repetitive intergenic consensus polymerase chain reaction technique (ERIC-PCR). We found a high prevalence and coexistence of genes encoding quinolone and aminoglycosides resistance that were heterogenous and mostly clonally unrelated.

The most common mechanism of aminoglycoside resistance arises from enzymatic modification rendering aminoglycosides unable to bind with the aminoacyl site of 16S rRNA with a subsequent failure to inhibit protein synthesis \[[@B1]\]. Modification of aminoglycosides is mediated by AMEs, which catalyze the modification at -OH or -NH~2~ groups of the 2-deoxystreptamine nucleus or of the sugar moieties of aminoglycoside molecules \[[@B2], [@B3]\], resulting in reduced or abolished binding of the aminoglycoside molecule to the ribosome. AMEs can be divided into three families: (i) aminoglycoside N-acetyltransferases (AACs), (ii) aminoglycoside O-phosphotransferases (APHs), and (iii) aminoglycoside O-nucleotidyltransferases (ANTs) \[[@B4]\]. Many of the AMEs result in clinically relevant resistance, but only APHs produce high-level resistance \[[@B2]\].

Regarding the quinolones, there are four known mechanisms of resistance that work separately or in combination, resulting in varying degrees of resistance that range from reduced susceptibility to clinically relevant resistance. These mechanisms may be chromosomal or plasmid-mediated \[[@B5]\]. The term "resistance" in the setting of PMQR refers to any increase in minimum inhibitory concentration (MIC) rather than to an increase above a susceptibility breakpoint \[[@B6]\]. Three mechanisms are responsible for PMQR: (i) target alteration by Qnr, (ii) drug modification by the aminoglycoside acetyltransferase AAC(6′)-Ib-cr, which can reduce ciprofloxacin activity, and (iii) efflux pump activation by two quinolone efflux pumps, which are known as OqxAB and QepA \[[@B6], [@B7]\].

Qnr proteins protect DNA gyrase and topoisomerase IV from the inhibitory activity of quinolones \[[@B8]\]. Currently, there are six different*qnr* genes:*qnrA*,*qnrB*,*qnrC*,*qnrD*,*qnrS,* and the most recently reported,*qnrVC* \[[@B6]\]. The sequences of*qnr* genes generally differ from each other and from*qnrA* by 35% \[[@B9]\]. Enzymatic inactivation of quinolones arises from aminoglycoside acetyltransferase \[AAC (6′)-Ib-cr\], which is a bifunctional variant of a common AAC(6′)-Ib. AAC(6′)-Ib-cr acetylates fluoroquinolones, such as ciprofloxacin and norfloxacin, that have an amino nitrogen on the C7 of piperazinyl ring \[[@B10]\]. Finally, we consider PMQR attributed to efflux pumps that specifically extrude quinolones from bacterial cells. Plasmid-mediated quinolone efflux involves two types of pumps, the quinolone efflux pump (QepA) and the olaquindox (OqxAB) efflux pump. QepA belongs to the major facilitator (MFS) family that decreases susceptibility to hydrophilic fluoroquinolones, especially ciprofloxacin and norfloxacin \[[@B7]\]. The*qepA* gene is often located on plasmids that encode aminoglycoside ribosomal methylase*(rmtB)* \[[@B6]\]. The OqxAB pump belongs to the resistance-nodulation-division (RND) family. The OqxAB pump was first detected on a conjugative plasmid (pOLA52) that was harbored by*Escherichia coli* strains isolated from swine manure \[[@B7], [@B11], [@B12]\]. The QqxAB efflux pump has wide substrate specificity that includes chloramphenicol, trimethoprim, and quinolones (ciprofloxacin, norfloxacin, and nalidixic acid \[[@B13]\]).*oqxAB* genes are located on plasmids in clinical isolates of*E. coli* and on both chromosomes and plasmids of*Salmonella* spp. and*K. pneumoniae*. We found that*oqxAB* genes are commonly located on the chromosome of*K. pneumoniae*\[[@B6], [@B14]\].

2. Materials and Methods {#sec2}
========================

2.1. Bacterial Strains {#sec2.1}
----------------------

A total of 114 nonduplicate clinical isolates of*K. pneumoniae*were selected from 301 randomly collected isolates of Gram-negative bacilli. The isolates of*K. pneumoniae* were collected from 84 cases (39 females and 45 males, age between 2 months and 85 years) who were admitted to or attended medical departments at Ain Shams University Hospital, Cairo, Egypt, over a period of one year (May 2012 to April 2013). Isolates of*K. pneumoniae*were recovered from ascitic fluid (*n* = 5), pus (*n* = 2), blood (*n* = 8), throat swab (*n* = 4), endotracheal tube (*n* = 1), sputum (*n* = 25), urinary catheter (*n* = 1), urine (*n* = 22), wound (*n* = 38), cerebrospinal fluid (*n* = 3), central line catheter (*n* = 3), surgical drain (*n* = 1), and nasal swab (*n* = 1).

2.2. Isolation and Identification of*K. pneumoniae*Isolates {#sec2.2}
-----------------------------------------------------------

All isolates of*K. pneumoniae*were initially isolated on MacConkey\'s agar (Oxoid, UK) and then subcultured on eosin methylene blue (EMB) agar (Scharlau, Spain). The isolated strains were identified phenotypically using API 20E (Biomerieux, France) and then confirmed genotypically through amplification of the specific*phoE*gene using primers and cycling conditions listed in [Table 1](#tab1){ref-type="table"}.

2.3. Genotyping of Clinical Isolates {#sec2.3}
------------------------------------

Clonal relatedness between clinical isolates of*K. pneumoniae*was determined by ERIC-PCR. The primer was obtained from Macrogen (Korea, Geumcheon-gu, Seoul). Gene amplification was carried out according to cycling conditions as described in [Table 1](#tab1){ref-type="table"} using Mastercycler® personal (Eppendorf, California, USA).

2.4. Fingerprint Pattern Analysis {#sec2.4}
---------------------------------

The banding pattern generated by ERIC-PCR was analyzed using BioNumerics 7.5 software (Applied Maths, Kortrijk, Belgium). The PCR fingerprint profile was analyzed using Dice (similarity) coefficient. Cluster analysis was performed based on the unweighted pair group method with arithmetic averages (UPGMA) at position tolerance at 0.15, as previously described \[[@B15]\].

2.5. Antimicrobial Susceptibility Testing {#sec2.5}
-----------------------------------------

All*K. pneumoniae*isolates were tested for susceptibility to 23 different antibiotics of several classes. Antimicrobial susceptibility testing was by Kirby-Bauer disc diffusion using Mueller-Hinton agar (MHA) (Oxoid, UK) \[[@B16]\]. Broth microdilution \[[@B17]\] was performed using cation-modified Mueller-Hinton broth (Oxoid, UK) to determine the MIC for the tested antibiotics by the Kirby-Bauer disc-diffusion method. Results were interpreted according to guidelines of the Clinical Laboratory Standards Institute (CLSI) \[[@B18]\]. Both*E. coli* ATCC 25922 and*K. pneumoniae* ATCC 700603 were used as quality-control strains.

2.6. Genotypic Detection of Genes Encoding Aminoglycoside and Quinolone Resistance {#sec2.6}
----------------------------------------------------------------------------------

All*K. pneumoniae* isolates that were resistant to amikacin and/or gentamicin were screened for 7 genes encoding AMEs, namely,*aac(3)-II*,*aac(6*′*)-Ib*,*aac(6*′*)-II*,*ant(3*′′*)-I*,*aph(3*′*)-VI*,*armA,*and*rmtB,* using primers and cycling conditions listed in [Table 1](#tab1){ref-type="table"}.

2.7. Genotypic Detection of Genes Encoding Quinolone Resistance {#sec2.7}
---------------------------------------------------------------

All*K. pneumoniae* isolates that were resistant to ciprofloxacin and/or levofloxacin were screened for 5 quinolone resistance proteins (*qnrA*,*qnrB*,*qnrC*,*qnrD,*and*qnrS*) and one quinolone-modifying enzyme,*acc(6*′*)-Ib-cr*. Also, 3 genes (*oqxA*,*oqxB,* and*qebA*) encoding quinolone efflux pump proteins were screened using primers and cycling conditions listed in [Table 2](#tab2){ref-type="table"}.

2.8. Preparation of DNA Templates {#sec2.8}
---------------------------------

DNA was extracted as previously described by Englen and Kelley \[[@B19]\]. Briefly, three to six colonies of bacterial isolates (depending on colony size) were picked from a nutrient agar plate and suspended in 100 *μ*l of DNase-free water in a sterile 1.5 ml microfuge tube to obtain a bacterial suspension equivalent to 1-2 × 10^9^ CFU/ml. The bacterial suspension was placed in a boiling water bath for 10 min to lyse the bacterial cells. The lysed bacterial suspension was centrifuged at maximum speed (13,000 ×g) for 3 min. The supernatant, which contains total genomic DNA, was transferred to a new sterile tube using DNase-free tips. DNA was stored in −20°C.

2.9. PCR Setup {#sec2.9}
--------------

The PCR reaction was performed at a final reaction volume of 20 *μ*l. The reaction mixture contained 4 *μ*l of extracted DNA, 4 *μ*l of 5x master mix (HOT FIREPol® Blend Master Mix, Solis BioDyne, Tartu, Estonia), 0.6 *μ*l of forward primer (10 pmol/*μ*l), 0.6 *μ*l of reverse primer (10 pmol/*μ*l), and 10.8 *μ*l distilled water.

3. Result {#sec3}
=========

3.1. Isolation and Identification {#sec3.1}
---------------------------------

From 301 recovered isolates, 114 (37%) were*K. pneumoniae*, 3 (1%) were*Klebsiella oxytoca*, 61 (20%) were*E. coli*, 48 (16%) were*Proteus*spp., 38 (13%) were*Pseudomonas aeruginosa*, 12 (4%) were*Acinetobacter baumannii*, 9 (3%) were*Serratia marcescens*, 6 (2%) were*Enterobacter cloacae,*and 3 (1%) were single isolates for each of*Providencia stuartii*,*Burkholderia cepacia,* and*Aeromonas hydrophilia*.

3.2. Phenotypic and Genotypic Identification of*K. pneumoniae* Isolates {#sec3.2}
-----------------------------------------------------------------------

Biotyping of*K. pneumoniae* clinical isolates using API 20E revealed 13 different biotypes. The most prevalent were 5215773 and 5205773, which occurred at a prevalence of 56% (64/114) and 29% (34/114), respectively. Other detected biotypes were 5005573, 5215573, and 5205573, which occurred at a prevalence of 3.5% (4/114), 1.8% (2/114), and 1.8% (2/114), respectively. The lowest detected biotypes were 1205773, 1215773, 5004573, 5204773, 5204553, 5215763, 5217773, and 5214773, which each occurred at a prevalence of 0.88% (1/114).

Genotypic confirmation of phenotypically identified isolates through amplification of the*K. pneumoniae phoE*gene revealed that these isolates were related to*K. pneumoniae*.

ERIC-PCR-based DNA fingerprinting identified only 95.6% (109/114) of the*K. pneumoniae*isolates, as 5 isolates gave no band following agarose gel electrophoresis. The 109 genotyped*K. pneumoniae* isolates displayed 85 different fingerprint patterns, as shown in [Figure 1](#fig1){ref-type="fig"}.

3.3. Fingerprint Pattern Analysis {#sec3.3}
---------------------------------

A UPGMA dendrogram generated according to Dice (similarity) coefficient revealed that the 85 fingerprint profiles were related to 67 different profiles, including 67 isolates with 18 different combined profiles that included 42 isolates. All genotyped*K. pneumoniae* were classified into 2 major phylogenetic groups (group A and group B), as shown in [Figure 2](#fig2){ref-type="fig"}. Phylogenetic group A included 4 isolates (K184, K109, K162, and K161). Two isolates (K161 and K162) within phylogenetic group A had the same fingerprint pattern. Phylogenetic group B contained the remaining 105 isolates.

3.4. Correlation between Phenotyping by API 20E and Genotyping by ERIC-PCR {#sec3.4}
--------------------------------------------------------------------------

No relationship was found between the phenotypes detected by API 20E and the genotypes detected by ERIC-PCR, as identical clones, such as KL169 and KL174, showed different biotypes (5005773 and 5215773). Other identical genotypes also revealed different biotypes, as shown in [Figure 2](#fig2){ref-type="fig"}.

3.5. Antimicrobial Susceptibility {#sec3.5}
---------------------------------

Antimicrobial susceptibility tests revealed that carbapenems (imipenem and meropenem) were more effective than 3rd- and 4th-generation cephalosporins for which 75% (86/114) and 75% (85/114) of the isolates were susceptible to imipenem and meropenem, respectively, as shown in [Table 3](#tab3){ref-type="table"}. Regarding non-*β*-lactam antibiotics, tigecycline showed the lowest resistance, as 97% (111/114) of isolates were susceptible. As regarding quinolones and aminoglycosides, we found that 60% (68/114), 26% (30/114), 47% (54/114), and 43% (49/114) of isolates were resistant to gentamicin, amikacin, ciprofloxacin, and levofloxacin, respectively.

Apart from imipenem and meropenem, the MIC~50~ and MIC~90~ values for other tested *β*-lactams ranged between 32 to 512 *μ*g/ml and 256 to \>1024 *μ*g/ml, respectively. On the other hand, the MIC~50~ and MIC~90~ for gentamicin and amikacin ranged from ≤0.5 to 8 *μ*g/ml and \>1024 *μ*g/ml, respectively, while MIC~50~ and MIC~90~ of ciprofloxacin and levofloxacin ranged from ≤0.5 to 1 *μ*g/ml and 64 to 128 *μ*g/ml, respectively.

3.6. Detection of Genes Encoding AMEs {#sec3.6}
-------------------------------------

Genotypic results for AMEs among the aminoglycoside-resistant isolates, as shown in [Figure 3](#fig3){ref-type="fig"}, revealed that acetyltransferases were the most prevalent type of AME. The*acc(6*′*)-Ib* and*acc(3*′*)-II* genes were detected among 88% (58/66) and 58% (38/66) of the investigated isolates ([Table 4](#tab4){ref-type="table"}). In contrast, the*acc(6*′*)-II* variant was not detected.

The second most common types of AME were phosphotransferases, followed by nucleotidyltransferases in which*aph(3*′*)-IV* and*ant(3*′*)-I* were detected among 50% (33/66) and 44% (29/66) of isolates, respectively. The lowest detected types of AMEs were ribosomal methylases in which*armA*was detected among 14% (9/66) of tested isolates. A*rmtB* variant was not detected.

3.7. Detection of Genes Encoding Qnr Proteins {#sec3.7}
---------------------------------------------

Screening of quinolone-resistant isolates for genes encoding Qnr proteins ([Figure 4](#fig4){ref-type="fig"}) revealed that*qnrB*was most prevalent (74% (42/57) tested positive). Other detected genes were*qnrS*and*qnrD,*which occurred at a prevalence of 49% (28/57) and 40% (23/57), respectively ([Table 4](#tab4){ref-type="table"}). The gene encoding Qnr protein detected least often was*qnrC*: only one isolate tested positive;*qnrA*was not detected.

3.8. Detection of Genes Encoding Quinolone Efflux Pumps {#sec3.8}
-------------------------------------------------------

The current study revealed that genes encoding*qebA, oqxA,* and*oqxB* efflux pumps were detected at a prevalence of 12% (7/57), 88% (50/58), and 30% (17/57), respectively, among the quinolone-resistant isolates. Only 26% (15/57) of the isolates harbored both*oqxA*and*oqxB*.

3.9. Detection of Gene Encoding Quinolone-Modifying Enzyme {#sec3.9}
----------------------------------------------------------

Screening for a quinolone-modifying enzyme among the quinolone-resistant isolates revealed that 61% (35/57) of the tested isolates harbored*acc(6*′*)-Ib-cr*.

3.10. Correlation between MIC for Quinolones and Aminoglycosides and Genetic Determinants of Resistance {#sec3.10}
-------------------------------------------------------------------------------------------------------

*K. pneumoniae*isolates that showed elevated MIC (16 to 256 *μ*g/ml) for ciprofloxacin and levofloxacin mainly harbored*qnrB* and*acc(6*′*)-Ib-cr*. Isolates that showed high MIC values (64 to ≥ 1024 *μ*g/ml) for gentamicin and amikacin harbored*aph(3*′*)-VI*and*ant(3*′′*)-I.*

4. Discussion {#sec4}
=============

Aminoglycoside-modifying enzymes are the most important determinants of aminoglycoside resistance among*K. pneumoniae* isolates \[[@B28]\]. The current study revealed that 88% (58/66) and 58% (38/66) of aminoglycoside-resistant*K. pneumoniae* isolates tested positive for*acc(6*′*)-Ib* and*acc(3*′*)-I,I,* respectively. Similar high prevalence rates for*acc(6*′*)-Ib* and*acc(3*′*)-II* among*K. pneumoniae* isolates were reported by Lotfollahi et al. (74% (63/85) and 73% (62/85) for*acc(6*′*)Ib*and*acc(3*′*)-II,* resp., \[[@B29]\]). But lower rates have also been reported (20% (32/162) and 30% (49/162) for*acc(6*′*)-Ib* and*acc (3*′*)-II,* resp., \[[@B30]\]). The present study also found that 44% (29/66) of aminoglycoside-resistant*K. pneumoniae* isolates tested positive for*ant(3*′′*)-1*, which is three times that seen previously (14% (22/162) \[[@B30]\]). For*aph(3*′*)-IV* we found that 50% (33/66) of the aminoglycoside-resistant*K. pneumoniae* isolates harbored this gene, which was similar to the findings of Almaghrabi et al. and Gad et al. (56% (28/50) and 50% (4/8), resp., \[[@B28], [@B31]\]).

The Qnr proteins are considered as one of the three reported mechanisms of PMQR. The*qnr* genes encode proteins that protect DNA gyrase and topoisomerase IV from inhibition by quinolones and have recently been found worldwide \[[@B32]\]. The current study examined the prevalence of Qnr proteins among*K. pneumoniae* isolates that showed full or intermediate resistance to quinolones. The*qnrA* gene was not detected, which was consistent with Yang et al. \[[@B32]\] but differed from a Portuguese study (19% (4/21) of MDR*K. pneumoniae* isolates \[[@B33]\] and another Egyptian report (12% (14/121) of ESBL-producing*K. pneumoniae* \[[@B34]\]). Regarding*qnrB*, we found that 74% (42/57) of the isolates tested positive, which was slightly more than the 50% (11/22) seen in a Korean study \[[@B32]\]. In contrast, a relatively low prevalence rate was reported by Tunisian study (13% (21/165) \[[@B35]\]). We found that*qnrC*was represented by only a single isolate, which was consistent with findings from the recent Turkish and Tunisian studies that failed to detect*qnrC*among quinolone-resistant*K. pneumoniae* isolates \[[@B35], [@B36]\]. The current study detected*qnrD* at a prevalence of 40% (23/57); previous work failed to detect this gene \[[@B35], [@B37]\]. The*qnrS* gene was seen in 49% (28/57) of the investigated*K. pneumoniae* isolates. Lower incidences (9% (2/22) and 2% (3/165)) had been reported in Korean \[[@B37]\] and Tunisian \[[@B35]\] studies, respectively. A much higher incidence (64%, 28/44) was reported in China \[[@B38]\]. We conclude that plasmids carrying*qnr* genes were highly spread in Egypt and China, probably due to misuse of quinolones in clinical settings.

The current work is the first Egyptian study to investigate the QepA and OqxAB efflux pumps among*K. pneumoniae* isolates. We found that 12% (7/57) tested positive for*qepA*, which is far higher than the 2% (5/247) reported previously \[[@B39]\] or the absence of*qebA* among*K. pneumoniae* isolates \[[@B40]\]. The prevalence of*oqxA*and*oqxB* was higher, 88% (50/57) and 30% (17/57), respectively. Previously Rodríguez-Martínez et al. reported values of 76% (87/114) and 75% (86/114), respectively \[[@B41]\]. Only 26% (15/57) of quinolone-resistant*K. pneumoniae* isolates were positive for both*oqxA*and*oqxB*, double that reported earlier (11% (11/102) \[[@B32]\]). Interestingly, Yuan et al. reported that 100% (154/154) of their*K. pneumoniae* isolates tested positive for both*oqxA* and*oqxB*, suggesting that in that case the genes encoding the OqxAB protein were located on the chromosome of*K. pneumoniae*, perhaps as a reservoir for these genes \[[@B42]\]. Thus, high resistance rates to quinolones may be expected among*K. pneumoniae*isolates recovered from clinical settings that frequently prescribe quinolones, since the chromosomal genes coding for OqxAB efflux pump proteins will be overexpressed.

Enzymatic modification of quinolones by the AAC(6′)-Ib-cr enzyme is a third reported mechanism underlying PMQR \[[@B32]\]. The current study revealed that 61% (35/57) of quinolone-resistant*K. pneumoniae* isolates tested positive for*aac(6*′*)-Ib-cr*, which is several times higher than seen by Jlili et al. and by Kim et al. (19% (8/42) and 13% (21/165), resp., \[[@B35], [@B43]\]).

Genotypic identification of*K. pneumoniae* isolates via amplification of*phoE* identified 81% (92/114) of the*K. pneumoniae* isolates; this finding contradicted Sun et al., who reported 100% \[[@B21]\]. This difference may be due to a mutation in the*phoE*gene of our isolates. Genotyping of*K. pneumoniae* isolates using the ERIC-PCR technique revealed that the majority of isolates had different origins; 32 isolates were related to 18 different single origins, indicating that the spread of*K. pneumoniae* among different hospital departments was due to poor infection control.

5. Conclusion {#sec5}
=============

The current study demonstrated that ACCs were the most prevalent AMEs, followed by APHs and then ANTs. Screening of*qnr* genes revealed that*qnrB* was the most prevalent, followed by*qnrS*. This is the first Egyptian study to detect*qnrC*and*acc(6*′*)-Ib-cr* among quinolone-resistant*K. pneumoniae*isolates. Genotypic identification of*K. pneumoniae* through amplification of the*phoE* gene was not 100%. Most*K. pneumoniae*isolates included in this study displayed different genetic and phenotypic profiles, indicating different origins of dissemination.
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![Representative DNA fingerprint pattern of*K. pneumoniae*clinical isolates genotyped by ERIC-PCR.](IJMICRO2017-8050432.001){#fig1}

![Generated UPGMA dendrogram based on Dice similarity coefficient for clustering of*K. pneumoniae*isolates using ERIC-PCR as DNA fingerprinting method. KL:*Klebsiella pneumoniae*, PGA: phylogenetic group A, and PGB: phylogenetic group B.](IJMICRO2017-8050432.002){#fig2}

![Representative PCR products of detected genes encoding AMEs. Lanes:**(1)***ant (3*′′*)-I*;**(L)** 100 bp ladder;**(2)***armA*;**(3)***acc(6*′*)-Ib*;**(4)***aph(3*′*)-VI*;**(5)***acc(3-)-II*.](IJMICRO2017-8050432.003){#fig3}

![Representative PCR products of detected quinolone resistance genes. Lanes:**(1)***qnrB*;**(2)***qnrC*;**(3)***qnrD*;**(4)***qnrS*;**(L)** 100 bp ladder;**(5)***acc(6*′*)-Ib-cr*;**(6)***oqxA*;**(7)***oqxb*;**(8)***qebA.*](IJMICRO2017-8050432.004){#fig4}

###### 

Primer sets and PCR cycling conditions used for genotyping and amplification of genes encoding AMES.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Primer       Sequence                          Gene             Reference    Amplification conditions                                                                                                                                                Amplicon size (bp)
  ------------ --------------------------------- ---------------- ------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  aac(3′)-II   **F**: ATATCGCGATGCATACGCGG\      *aac(3*′*)-II*   \[[@B20]\]   *Initial denaturation* at 95°C for 15 min, then *30 cycles of* 95°C for 1 min, 55°C for 1 min, and 72°C for 5 minutes, and *one cycle* of *final elongation* at 72°C.   877
               **R**: GACGGCCTCTAACCGGAAGG                                                                                                                                                                                                             

                                                                                                                                                                                                                                                       

  aac(6′)-Ib   **F**: TTGCGATGCTCTATGAGTGGCTA\   *aac(6*′*)-Ib*   \[[@B20]\]   *Initial denaturation* at 95°C for 15 min, then *30 cycles of* 95°C for 1 min, 55°C for 1 min, and 72°C for 5 minutes, and *one cycle* of *final elongation* at 72°C.   472
               **R**: CTCGAATGCCTGGCGTGTTT                                                                                                                                                                                                             

  aac(6′)-II   **F**: CGACCATTTCATGTCC\          *aac(6*′*)-II*   \[[@B20]\]   542                                                                                                                                                                     
               **R**: GAAGGCTTGTCGTGTTT                                                                                                                                                                                                                

                                                                                                                                                                                                                                                       

  ant(3′′)-I   **F**: CATCATGAGGGAAGCGGTG\       *ant(3*′′*)-I*   \[[@B20]\]   *Initial denaturation* at 95°C for 15 min, then *30 cycles of* 95°C for 1 min, 55°C for 1 min, and 72°C for 5 minutes, and *one cycle* of *final elongation* at 72°C.   787
               **R**: GACTACCTTGGTGATCTCG                                                                                                                                                                                                              

                                                                                                                                                                                                                                                       

  aph(3′)-VI   **F**: ATGGAATTGCCCAATATTATT\     *aph(3*′*)-VI*   \[[@B20]\]   *Initial denaturation* at 95°C for 15 min, then *30 cycles of* 95°C for 1 min, 55°C for 1 min, and 72°C for 5 minutes, and *one cycle* of *final elongation* at 72°C.   780
               **R**: TCAATTCAATTCATCAAGTTT                                                                                                                                                                                                            

  armA         **F**: CCGAAATGACAGTTCCTATC\      *armA*           \[[@B20]\]   846                                                                                                                                                                     
               **R**: GAAAATGAGTGCCTTGGAGG                                                                                                                                                                                                             

                                                                                                                                                                                                                                                       

  rmtB         **F**: ATGAACATCAACGATGCCCTC\     *rmtB*           \[[@B20]\]   *Initial denaturation* at 95°C for 15 min, then *30 cycles of* 95°C for 1 min, 60°C for 1 min, and 72°C for 5 minutes, and *one cycle* of *final elongation* at 72°C.   769
               **R**: CCTTCTGATTGGCTTATCCA                                                                                                                                                                                                             

                                                                                                                                                                                                                                                       

  phoE         **F**: TGGCCCGCGCCCAGGGTTCGAAA\   *phoE*           \[[@B21]\]   *Initial denaturation* at 95°C for 15 min, then *35 cycles of* 95°C for 1 min, 40°C for 1 min, and 72°C for 5 minutes, and *one cycle* of *final elongation* at 72°C.   368
               **R**: GATGTCGTCATCGTTGATGCCGAG                                                                                                                                                                                                         

  ERIC-1R      **R**: AACCCACGATGTGGGTAGC        ---              \[[@B22]\]   ---                                                                                                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

acc: aminoglycoside acetyl transferase, ant: aminoglycoside nucleotidyl transferase, aph: aminoglycoside phosphor transferase, arm: aminoglycoside ribosomal methylase, and rmt: ribosomal methylase, phoE; phosphoporin E, ERIC, enterobacterial repetitive intergenic consensus.

###### 

Primer sets and PCR cycling conditions used for amplification of genes encoding quinolone resistance.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Prime            Sequence                          Gene                 Reference    Amplification conditions                                                                                                                                                Amplicon size (bp)
  ---------------- --------------------------------- -------------------- ------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  QnrA             **F**: AGAGGATTTCTCACGCCAGG\      qnrA                 \[[@B23]\]   *Initial denaturation* at 95°C for 15 min, then *30 cycles of* 95°C for 1 min, 55°C for 1 min, and 72°C for 5 minutes, and *one cycle* of *final elongation* at 72°C.   580
                   **R**: TGCCAGGCACAGATCTTGAC                                                                                                                                                                                                                 

  QnrB             **F**: GGMATHGAAATTCGCCACTG\      *qnrB*               \[[@B23]\]   264                                                                                                                                                                     
                   **R**: TTTGCYGYYCGCCAGTCGAA                                                                                                                                                                                                                 

  QnrC             **F**: GGGTTGTACATTTATTGAATCG\    *qnrC*               \[[@B24]\]   307                                                                                                                                                                     
                   **R**: CACCTACCCATTTATTTTCA                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                               

  QnrD             **F**: CGAGATCAATTTACGGGGAATA\    *qnrD*               \[[@B24]\]   *Initial denaturation* at 95°C for 15 min, then *30 cycles of* 95°C for 1 min, 56°C for 1 min, and 72°C for 5 minutes, and *one cycle* of *final elongation* at 72°C.   533
                   **R**: AACAAGCTGAAGCGCCTG                                                                                                                                                                                                                   

  QnrS             **F**: GCAAGTTCATTGAACAGGGT\      *qnrS*               \[[@B23]\]   428                                                                                                                                                                     
                   **R**: TCTAAACCGTCGAGTTCGGCG                                                                                                                                                                                                                

  ACC (6′)-Ib-cr   **F**: TTGCGATGCTCTATGAGTGGCTA\   *acc (6*′*)-Ib-cr*   \[[@B25]\]   482                                                                                                                                                                     
                   **R**: CTCGAATGC-CTGGCGTGTTT                                                                                                                                                                                                                

                                                                                                                                                                                                                                                               

  OqxA             **F**: CTCGGCGCGATGATGCT\         *oqxA*               \[[@B26]\]   *Initial denaturation* at 95°C for 15 min, then *30 cycles of* 95°C for 1 min, 60°C for 1 min, and 72°C for 5 minutes, and *one cycle* of *final elongation* at 72°C.   392
                   **R**: CCACTCTTCACGGGAGACGA                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                               

  OqxB             **F**: TTCTCCCCCGGCGGGAAGTAC\     *oqxB*               \[[@B26]\]   *Initial denaturation* at 95°C for 15 min, then *35 cycles of* 95°C for 1 min, 58°C for 1 min, and 72°C for 5 minutes, and *one cycle of final elongation* at 72°C.     512
                   **R**: CTCGGCCATTTTGGCGCGTA                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                               

  Qep              **F**: AACTGCTTGAGCCCGTAGAT\      *qepA*               \[[@B27]\]   *Initial denaturation* at 95°C for 15 min, then *30 cycles of* 95°C for 1 min, 55°C for 1 min, and 72°C for 5 minutes, and *one cycle* of *final elongation* at 72°C.   596
                   **R**: GTCTACGCCATGGACCTCAC                                                                                                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

qnr: quinolone resistance protein, acc(6′)-Ib-cr: aminoglycoside acetyl transferase-ciprofloxacin variant, Oqx: olaquindox, and Qep: quinolone efflux pump.

###### 

Antibiotic susceptibility of *K. pneumoniae* clinical isolates.

  Antibiotic               *K. pneumoniae* susceptibility pattern (*n* = 114)   MIC~50~ and MIC~90~                         
  ------------------------ ---------------------------------------------------- --------------------- -------------- ------ --------
  Cefotaxime               15 **(13)**                                          1 **(1)**             98 **(86)**    256    \>1024
  Ceftazidime              26 **(23)**                                          14 **(12)**           74 **(65)**    32     \>1024
  Cefoperazone             17 **(15)**                                          3 **(2)**             94**(82)**     512    \>1024
  Cefoperazone/sulbactam   51 **(45)**                                          12 **(10)**           51 **(45)**    32     1024
  Ceftriaxone              18**(16)**                                           ---                   96 **(84)**    256    \>1024
  Cefepime                 21 **(18)**                                          24**(21)**            69**(61)**     32     256
  Imipenem                 86 **(75)**                                          5 **(4)**             23 **(20)**    ≤0.5   4
  Meropenem                85 **(75)**                                          2 **(2)**             27 **(24)**    ≤0.5   16
  Tetracycline             32 **(28)**                                          4 **(3)**             78 **(68)**    128    512
  Tigecycline              111 **(97)**                                         ---                   3 **(3.0)**    ≤0.5   ≤0.5
  Gentamicin               46 **(40)**                                          12 **(11)**           56 **(49)**    8      \>1024
  Amikacin                 84 **(74)**                                          1 **(1)**             29 **(25)**    ≤0.5   \>1024
  Thiamphenicol            7 **(6.0)**                                          2 **(2)**             105 **(92)**   1024   \>1024
  Ciprofloxacin            60 **(53)**                                          3 **(2)**             51 **(45)**    1      128
  Levofloxacin             65 **(57)**                                          5 **(4)**             44 **(39)**    ≤0.5   64

###### 

Resistance pattern and genetic profile of quinolone and aminoglycoside resistant *K. pneumoniae*isolates.

  Isolate number   Quinolone and aminoglycoside resistance profile   Quinolone resistance genetic profile                             Number of quinolone resistance genes   Aminoglycoside resistance genetic profile                         Number of aminoglycoside resistance genes   Total number of detected genes
  ---------------- ------------------------------------------------- ---------------------------------------------------------------- -------------------------------------- ----------------------------------------------------------------- ------------------------------------------- --------------------------------
  KLP2             CN, AK, CIP                                       *qnrB*,*qnrD*, *oqxA*, *oqxB*                                    4                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*                                     2                                           6
  KLP3             CN, CP, LEV                                       *qnrB*,*qnrD*,*oqxA*                                             3                                      *aac(3)-II*,*aac(6*′*)-Ib*                                        2                                           5
  KLP5             CN                                                NA                                                               NA                                     *aac(3)-II*,*aac(6*′*)-Ib*                                        2                                           2
  KLP6             CN                                                NA                                                               NA                                     *aac(3)-II*,*aac(6*′*)-Ib*                                        2                                           5
  KLP13            CN, AK, CIP, LEV                                  *qnrB*,*oqxA*, *oqxB*                                            3                                      ---                                                               ---                                         3
  KLP14            CN, AK, CIP, LEV                                  *qnrB*                                                           1                                      *aph(3*′*)-VI*, *ant(3*′′*)-I*                                    2                                           3
  KLP15            CN, AK, CIP                                       *qnrB*,*oqxA*, *acc(6*′*)-Ib-cr*                                 3                                      *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*,*armA*   5                                           8
  KLP19            CN, AK, CIP, LEV                                  *qnrB*,*oqxA*, *oqxB*                                            3                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*                                     2                                           5
  KLP20            CN, AK, CIP, LEV                                  *qnrB*,*oqxA*                                                    2                                      *aac(3)-II*,*aac(6*′*)-Ib*                                        2                                           4
  KLP23            CN, AK, CIP, LEV                                  *qnrB*,*qnrD*, *qnrS*,*oqxA*                                     4                                      *aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*                         3                                           7
  KLP27            CN, CIP, LEV                                      *qnrB*,*qnrD*,*oqxA*                                             3                                      *aac(3)-II*,*aac(6*′*)-Ib*                                        2                                           5
  KLP28            CN, CIP, LEV                                      *qnrB*,*oqxA*                                                    2                                      *aac(6*′*)-Ib*, *aph(3*′*)-VI*,*armA*                             3                                           5
  KLP29            CN, AK, CIP                                       *qnrB*,*oqxA*                                                    2                                      *ant(3*′′*)-I*, *aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*         4                                           6
  KLP30            CN, AK, CIP, LEV                                  *qnrB*, *qnrS*,*oqxA*, *oqxB*, *acc(6*′*)-Ib-cr*                 5                                      *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*          4                                           9
  KLP33            CN, CIP, LEV                                      *qnrB*, *qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                         4                                      *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*          4                                           8
  KLP34            CN                                                *oqxA*                                                           1                                      *aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*                         3                                           4
  KLP35            CN, CIP                                           *acc(6*′*)-Ib-cr*                                                1                                      *aac(6*′*)-Ib*, *aac(6*′*)-Ib*,*aph(3*′*)-VI*                     3                                           4
  KLP36            CN, AK, CIP, LEV                                  *oqxA*                                                           1                                      *aac(3)-II*,*aac(6*′*)-Ib*                                        2                                           3
  KLP42            CN                                                NA                                                               NA                                     *aac(3)-II*,*aac(6*′*)-Ib*                                        2                                           2
  KLP43            CN                                                NA                                                               NA                                     *aac(3)-II*, *aac(6*′*)-Ib*, *aph(3*′*)-VI*                       3                                           3
  KLP50            CN, LEV                                           *qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                                 3                                      *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*                         3                                           6
  KLP58A           CIP, LEV                                          *qnrB*, *qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                         4                                      NA                                                                NA                                          4
  KLP58B           CN, CIP, LEV                                      *qnrB*, *qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                         4                                      *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*, *aph(3*′*)-VI*         4                                           8
  KLP63            CN, AK, CIP, LEV                                  *qnrB*,*oqxA*, *acc(6*′*)-Ib-cr*                                 3                                      *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*          4                                           7
  KLP65            CN                                                NA                                                               NA                                     *aac(6*′*)-Ib*                                                    1                                           1
  KLP69            CN, AK, CIP, LEV                                  *qnrB*,*qnrD*,*oqxA*, *oqxB*, *acc(6*′*)-Ib-cr*                  5                                      ---                                                               ---                                         5
  KLP72            CN, AK, CIP, LEV                                  *qnrB*,*qnrD*, *qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                  5                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*,*armA*               4                                           9
  KLP73            CN                                                NA                                                               NA                                     *aac(6*′*)-Ib*                                                    1                                           1
  KLP78            CN, CIP, LEV                                      *qnrB*,*qnrD*, *oqxA*                                            3                                      *aac(3)-II*,*aac(6*′*)-Ib*                                        2                                           5
  KLP80            CN, AK, CIP, LEV                                  *qnrD*, *qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                         4                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*,*armA*               4                                           8
  KLP81            CN, CIP                                           *qnrB*,*oqxA*, *acc(6*′*)-Ib-cr*                                 3                                      *aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*                         3                                           6
  KLP88            CN                                                NA                                                               NA                                     *aac(3)-II*, *aac(6*′*)-Ib*,*aph(3*′*)-VI*                        3                                           3
  KLP89            CN, AK                                            NA                                                               NA                                     *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*, *aph(3*′*)-VI*         4                                           4
  KLP93            CN                                                NA                                                               NA                                     *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*          4                                           4
  KLP96            CN, AK, CIP, LEV                                  *qnrB*,*qnrD*, *qnrS*,*qebA*,*oqxA*, *oqxB*, *acc(6*′*)-Ib-cr*   7                                      *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*,*armA*   5                                           12
  KLP99            CN, AK, CIP, LEV                                  *qnrB*, *oqxA*, *oqxB*, *acc(6*′*)-Ib-cr*                        4                                      *aac(6*′*)-Ib*,*aph(3*′*)-VI*                                     2                                           6
  KLP100           CN, AK, CIP, LEV                                  *qnrB*, *oqxA*, *oqxB*, *acc(6*′*)-Ib-cr*                        4                                      *aac(3)-II*,*aac(6*′*)-Ib*                                        2                                           6
  KLP101           CN, CIP, LEV                                      *qnrB*, *oqxA*, *acc(6*′*)-Ib-cr*                                3                                      *aac(6*′*)-Ib*, *aph(3*′*)-VI*                                    2                                           5
  KLP102           CIP, LEV                                          *qnrD*,*oqxA*                                                    2                                      NA                                                                NA                                          2
  KLP103           CN, AK, CIP, LEV                                  *qnrB*, *oqxA*, *oqxB*                                           3                                      *aac(6*′*)-Ib*,*aph(3*′*)-VI*                                     2                                           5
  KLP104           CN, CIP, LEV                                      *qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                                 3                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*                                     2                                           5
  KLP107           CN                                                NA                                                               NA                                     *aac(6*′*)-Ib*                                                    1                                           1
  KLP108           CN, LEV                                           *qnrB*,*qnrS*, *acc(6*′*)-Ib-cr*                                 3                                      *aac(3)-II*, *aac(6*′*)-Ib*                                       2                                           5
  KLP110           CN, CIP, LEV                                      *qnrB*,*qnrD*, *qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                  5                                      *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*, *aph(3*′*)-VI*         4                                           9
  KLP111           CN                                                NA                                                               NA                                     *ant(3*′′*)-I*,*aac(3)-II*,*aph(3*′*)-VI*                         3                                           3
  KLP112           CN, CIP, LEV                                      *qnrB*,*qnrD*,*qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                   5                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*                      3                                           8
  KLP115           CN, CIP, LEV                                      *qnrB*,*qnrD*,*qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                   5                                      *aac(6*′*)-Ib*                                                    1                                           6
  KLP117           CIP, LEV                                          *qnrB*,*qnrD*,*qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                   5                                      NA                                                                NA                                          5
  KLP119           CN                                                NA                                                               NA                                     *aac(3)-II*                                                       1                                           1
  KLP121           CIP, LEV                                          *qnrB*,*qnrD*,*qnrS*,*oqxA*, *oqxB*                              5                                      NA                                                                NA                                          5
  KLP125           CN, AK, CIP, LEV                                  *qnrB*,*qebA*,*oqxA*, *oqxB*, *acc(6*′*)-Ib-cr*                  5                                      *aac(6*′*)-Ib*                                                    1                                           6
  KLP127           CN, AK, CIP, LEV                                  *qnrB*,*qnrD*,*qebA*,*oqxA*, *oqxB*, *acc(6*′*)-Ib-cr*           6                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*                                     2                                           8
  KLP128           CN                                                NA                                                               NA                                     ---                                                               ---                                         ---
  KLP129           CN, AK, CIP, LEV                                  *qnrB*,*qnrS*, *qebA*,*oqxA*, *acc(6*′*)-Ib-cr*                  5                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*,*armA*               4                                           9
  KLP134           CN, AK, CIP, LEV                                  *qnrB*,*qnrS*,*oqxA*, *oqxB*, *acc(6*′*)-Ib-cr*                  5                                      *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*          4                                           9
  KLP136           CIP, LEV                                          *qnrS*, *oqxB*                                                   2                                      *aac(6*′*)-Ib*                                                    1                                           3
  KLP137           CIP, LEV                                          *qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                                 3                                      NA                                                                NA                                          3
  KLP140           CN                                                NA                                                               NA                                     *aac(3)-II*                                                       1                                           1
  KLP141           CN                                                NA                                                               NA                                     *aac(3)-II*                                                       1                                           1
  KLP144           CN, AK, CIP, LEV                                  *acc(6*′*)-Ib-cr*                                                1                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*                      3                                           4
  KLP147           CN, LEV                                           *qnrB*,*qnrD*,*qnrS*,*oqxA*, *acc(6*′*)-Ib-cr*                   5                                      *aac(3)-II*,*aac(6*′*)-Ib*                                        2                                           7
  KLP148           CN                                                NA                                                               NA                                     ---                                                               ---                                         ---
  KLP154           CIP                                               *qnrB*,*qnrD*,*qnrS*,*oqxA*                                      4                                      NA                                                                NA                                          4
  KLP157           CN                                                NA                                                               NA                                     *aac(3)-II*, *aac(6*′*)-Ib*,*aph(3*′*)-VI*                        3                                           3
  KLP169           CN, AK, CIP, LEV                                  *qnrB*, *oqxA*, *acc(6*′*)-Ib-cr*                                3                                      *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*          4                                           7
  KLP170           CN, AK, CIP, LEV                                  *qnrB*, *oqxA*,*oqxB*, *acc(6*′*)-Ib-cr*                         4                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*                      3                                           7
  KLP177           CN, CIP, LEV                                      ---                                                              ---                                    ---                                                               ---                                         ---
  KLP180           CN, AK, CIP, LEV                                  *qnrB*,*qnrD*,*qnrS*,*oqxA*,*oqxB*, *acc(6*′*)-Ib-cr*            6                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*                                     2                                           8
  KLP184           CIP, LEV                                          *qnrS*,*oqxA*,*oqxB*                                             3                                      NA                                                                NA                                          3
  KLP186           CN, CIP                                           *qnrC*,*qnrD*, *qnrS*,*oqxA*                                     4                                      *aac(6*′*)-Ib*                                                    1                                           5
  KLP187           CIP                                               *qnrS*,*qnrD*                                                    2                                      NA                                                                NA                                          2
  KLP197           CN, AK, CIP, LEV                                  *qnrS*,*qebA*,*oqxA*, *acc(6*′*)-Ib-cr*                          4                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*,*armA*               4                                           8
  KLP198           CN, AK, CIP, LEV                                  *qnrB*,*qnrD*,*qebA*,*oqxA*, *acc(6*′*)-Ib-cr*                   5                                      *aac(3)-II*,*aac(6*′*)-Ib*                                        2                                           7
  KLP199           CN                                                NA                                                               NA                                     *aac(3)-II*,*aac(6*′*)-Ib*                                        2                                           2
  KLP201           CN, CIP, LEV                                      *qnrB*,*qnrD*,*oqxA*                                             3                                      *ant(3*′′*)-I*,*aac(3)-II*,*aac(6*′*)-Ib*,*aph(3*′*)-VI*,*armA*   5                                           8
  KLP207           CN, AK, CIP, LEV                                  *qnrB*,*qnrS*, *qebA*,*oqxA*, *acc(6*′*)-Ib-cr*                  5                                      *ant(3*′′*)-I*,*aac(6*′*)-Ib*, *armA*                             3                                           8

KL: *Klebsiella pneumoniae*, CN: gentamicin, AK: amikacin, CIP: ciprofloxacin, LEV: levofloxacin, and NA: not applicable.

[^1]: Academic Editor: Karl Drlica
